Predictors of response to corticosteroids for dyspnea in advanced cancer patients: a preliminary multicenter prospective observational study
- PMID: 27900548
- DOI: 10.1007/s00520-016-3507-5
Predictors of response to corticosteroids for dyspnea in advanced cancer patients: a preliminary multicenter prospective observational study
Abstract
Purpose: Although corticosteroids can relieve dyspnea in advanced cancer patients, factors predicting the response remain unknown. We aimed to explore potential factors predicting the response to corticosteroids for dyspnea in advanced cancer patients.
Methods: In this preliminary multicenter prospective observational study, we included patients who had metastatic or locally advanced cancer, were receiving specialized palliative care services, and had a dyspnea intensity of ≥3 on a 0-10 Numerical Rating Scale (NRS) (worst during the last 24 h). The primary endpoint was NRS of dyspnea on day 3 after the administration of corticosteroids. Univariate/multivariate analyses were conducted to identify factors predicting ≥1-point reduction in NRS.
Results: Of 74 patients who received corticosteroids, 50 (68%) showed ≥1-point reduction in dyspnea NRS. Factors that significantly predicted the response were an age of 70 years or older (82 vs. 53%, p = 0.008), absence of liver metastases (77 vs. 46%, p = 0.001), Palliative Prognostic Index (PPI) ≤ 6 (90 vs. 61%, p = 0.041), presence of pleuritis carcinomatosa with a small collection of pleural effusions (84 vs. 55%, p = 0.011), presence of audible wheezes (94 vs. 60%, p = 0.014), and baseline dyspnea NRS ≥7 (76% vs. 52%, p = 0.041). In a multivariate analysis, factors predicting response included PPI <6 (odds ratio (OR), 36.2; p = 0.021), baseline dyspnea NRS (worst) ≥7 (OR, 6.6; p = 0.036), and absence of liver metastases (OR, 0.19; p = 0.029) or ascites/liver enlargement (OR, 0.13; p = 0.050).
Conclusions: The patient characteristics, etiologies of dyspnea, and clinical manifestations may predict responses to corticosteroids for dyspnea. Larger prospective studies are promising to confirm our findings.
Keywords: Cancer; Corticosteroids; Dyspnea; Palliative care; Predictors.
Similar articles
-
Predictors of Responses to Corticosteroids for Cancer-Related Fatigue in Advanced Cancer Patients: A Multicenter, Prospective, Observational Study.J Pain Symptom Manage. 2016 Jul;52(1):64-72. doi: 10.1016/j.jpainsymman.2016.01.015. Epub 2016 May 24. J Pain Symptom Manage. 2016. PMID: 27233138
-
Predictors of responses to corticosteroids for anorexia in advanced cancer patients: a multicenter prospective observational study.Support Care Cancer. 2017 Jan;25(1):41-50. doi: 10.1007/s00520-016-3383-z. Epub 2016 Aug 18. Support Care Cancer. 2017. PMID: 27539132
-
Predictors of Delirium in Corticosteroid-Treated Patients with Advanced Cancer: An Exploratory, Multicenter, Prospective, Observational Study.J Palliat Med. 2017 Apr;20(4):352-359. doi: 10.1089/jpm.2016.0323. Epub 2017 Feb 28. J Palliat Med. 2017. PMID: 28379811
-
Symptomatic treatment of dyspnea in advanced cancer patients : A narrative review of the current literature.Wien Med Wochenschr. 2018 Oct;168(13-14):333-343. doi: 10.1007/s10354-017-0600-4. Epub 2017 Sep 18. Wien Med Wochenschr. 2018. PMID: 28921042 Review.
-
Contemporary drug therapy in palliative care: new directions.Cancer Invest. 2001;19(4):413-23. doi: 10.1081/cnv-100103135. Cancer Invest. 2001. PMID: 11405180 Review. No abstract available.
Cited by
-
Fentanyl treatment for end-of-life dyspnoea relief in advanced cancer patients.Support Care Cancer. 2019 Jan;27(1):157-164. doi: 10.1007/s00520-018-4309-8. Epub 2018 Jun 18. Support Care Cancer. 2019. PMID: 29915993
-
Physician-Perceived Predictive Factors for the Effectiveness of Drugs for Treating Cancer Dyspnea: Results of a Nationwide Survey of Japanese Palliative Care Physicians.Palliat Med Rep. 2020 Jun 30;1(1):97-102. doi: 10.1089/pmr.2020.0050. eCollection 2020. Palliat Med Rep. 2020. PMID: 34223464 Free PMC article.
-
Unanswered questions and future direction in the management of terminal breathlessness in patients with cancer.ESMO Open. 2020;5 Suppl 1(Suppl 1):e000603. doi: 10.1136/esmoopen-2019-000603. Epub 2020 Sep 30. ESMO Open. 2020. PMID: 33558034 Free PMC article. Review.
-
Current Management Options for Dyspnea in Cancer Patients.Curr Treat Options Oncol. 2023 Jun;24(6):565-579. doi: 10.1007/s11864-023-01081-4. Epub 2023 Apr 11. Curr Treat Options Oncol. 2023. PMID: 37037975 Review.
-
Systematic review of the literature on the occurrence and characteristics of dyspnea in oncology patients.Crit Rev Oncol Hematol. 2023 Jan;181:103870. doi: 10.1016/j.critrevonc.2022.103870. Epub 2022 Nov 12. Crit Rev Oncol Hematol. 2023. PMID: 36375635 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical